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ABSTRACT
Objective: This study evaluated the efficacy of pentoxifylline, a hemorrheologic agent, for treating acute ischemic stroke in patients with blood 
hyperviscosity.
Methods: Patients were randomly allocated within 3 days of stroke onset to study or control treatment. All the patients received the standard acute 
ischemic stroke treatment. The study treatment was intravenous pentoxifylline 1200 mg/day for 5 consecutive days and oral pentoxifylline 800 mg 
in two divided doses for 23 days. Blood viscosity was evaluated on days 7 and 30. The outcomes were assessed by the National Institutes of Health 
Stroke Scale (NIHSS), modified Rankin Scale, and Barthel index (BI) criteria.
Results: The median baseline viscosity was 6.89 poise in the study and 6.46 poise in the control groups and had decreased in all the patients on 
days 7 and 30. The decrease in the study group on day 7 (1.13 poise) was greater than that in the control group (0.57 poise); the difference was not 
significant. The NIHSS score improved by 32% in the study group (relative risk [RR]=1.00, 95% confidence interval [CI]: 0.421–3.556; p=1.00). At 
1-month, 67% of the study group had a good functional outcome (RR=1.026, 95% CI: 0.656–1.605; p=0.909).
Conclusion: Pentoxifylline decreased blood viscosity and improved clinical outcome in this patient series.
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INTRODUCTION
In Indonesia, the most common cause of death from a noncommunicable 
disease is stroke. The incidence of stroke increased from 8.3/1000 
population, in 2007, to 12.1/1000 population, in 2013 [1]. Stroke can 
cause long-term disability [2], in 2014, 71.4% of the stroke patients 
admitted to the Neurology Department of Cipto Mangunkusumo General 
Hospital RSCM (Rumah Sakit Cipto Mangunkusumo) experienced ischemic 
stroke [3]. Ischemic stroke is caused by sudden loss of blood circulation 
to the brain, spinal cord, or retina due to embolism, thrombosis, or 
perfusion abnormalities such as blood hyperviscosity [4]. Regions of 
cerebrovascular ischemia include two areas of injury, a core zone of cell 
death and an ischemic penumbra that can be salvaged [5].
Blood hyperviscosity is present in 40% of patients with acute 
ischemic stroke and contributes to the severity of clinical outcome [6]. 
Hematocrit, erythrocyte deformability, erythrocyte aggregation, and 
fibrinogen determine blood viscosity [7]. It is important to determine 
blood viscosity because hyperviscosity in the penumbra can decrease 
cerebral blood flow and lead to infarction [8]. In Indonesia, the 
measurement of blood viscosity in patients with acute ischemic stroke 
is not routine because until now it could be done in large laboratories 
only and the result could not be obtained right away. In this study, a 
novel digital microcapillary instrument was used to screen blood 
viscosity [9].
The Indonesian national health insurance values effective, efficient 
treatment. Since intravenous thrombolysis can only be administered 
to 10% of acute ischemic stroke patients due to the narrow time 
window [10], 90% of patients require an alternative therapy to protect 
the penumbra from infarction. Pentoxifylline, a methylxanthine 
derivative, inhibits cyclic adenosine monophosphate phosphodiesterase 
and cyclic guanosine monophosphate hydrolysis and blocks the 
adenosine transporter and the phospholipase. Methylxanthines 
inhibit platelet aggregation and thromboxane A2 synthesis, increase 
phagocytic activity, and increase the synthesis of prostacyclin from 
endoperoxidase. They lower blood viscosity by increasing erythrocyte 
stability, by reducing the aggregation of erythrocytes and plasma 
fibrinogen concentration, and may be neuroprotective by inhibiting 
glutamate release [11]. Pentoxifylline may improve cerebral blood flow 
and may suppress inflammation in acute stroke [12,13], but a marker 
of its efficacy is lacking. In this study, blood hyperviscosity was used as 
a marker of the effectiveness of pentoxifylline in acute stroke patients. 
The device used in this study called “Digital Microcapillary” is a portable 
device to measure blood viscosity that has been patented in Indonesia 
since 2016 with patent number 0000431D8 from the Ministry of Law 
and Human Rights of Republic of Indonesia.
METHODS
Subjects
Adult acute ischemic stroke patients with blood hyperviscosity treated 
at the Cipto Mangunkusumo General and Prikasih Hospital between 
September 1st, 2016, and June 31, 2017, were recruited within 3 days 
of onset. Physical and neurologic examinations were performed by the 
doctor on duty. Ischemic stroke was diagnosed by cerebral computed 
tomography. Stroke symptoms were classified by the Bamford criteria; 
patients with posterior circulation infarct or total anterior cerebral 
infarct were excluded. Patients with dehydration (a urea/creatinine 
ratio >32 on admission), previous history of stroke or transient 
ischemic attack, previous intravenous or intra-arterial thrombolysis, or 
an estimated glomerular filtration rate of <30% were excluded.
Study design and procedures
In this single-blind controlled study, eligible patients were assigned 
by block randomization to receive pentoxifylline or control treatment 
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(no pentoxifylline). All the subjects received the standard treatment for 
acute ischemic stroke, including an antithrombotic agent, statin, and 
other medications if indicated, such as antiepileptic agents for seizures 
or antibiotics for pneumonia or other infections. The study group 
received intravenous pentoxifylline 1200 mg/day for 5 consecutive 
days followed by oral pentoxifylline 800 mg in two divided doses for 
23 days. The study protocol was approved by the Health Research Ethics 
Committee of the University of Indonesia and Cipto Mangunkusumo 
Hospital (HREC-FMUI/CMH) and was conducted following the ethical 
principles of the Declaration of Helsinki. All the participants gave 
written informed consent.
Blood viscosity was measured on the day of admission, day 7, and day 
30 day using a digital microcapillary device previously described by 
Rasyid et al. [9]. The neurological deficit was assessed on admission 
and day 7 by the National Institutes of Health Stroke Scale (NIHSS) 
score. Significant improvement was defined as a 4-point change from 
the baseline score or a score of 0. Disability and functional outcome 
were assessed by the modified Rankin Scale (mRS) and Barthel index 
(BI) on day 30. A poor disability outcome was defined as an mRS score 
of >3, and a poor functional outcome was defined as a BI score of <60.
Statistical analysis
Numerical data were reported as means ± standard deviation if normally 
distributed or as median and range if not normally distributed. Categorical 
data were reported as frequencies and percentages. Statistical analysis 
was performed with SPSS version 20 (IBM Cor., Armonk, NY, USA). 
Independent t test or Mann–Whitney U-tests was used to compare means; 
Chi-square or Fisher’s exact tests were used to compare percentages.
RESULTS AND DISCUSSION
A total of 44 patients met the eligibility criteria and were willing to 
participate; 42 were admitted to RSUPN Cipto Mangunkusumo and two 
were admitted to Prikasih Hospital. 22 patients received pentoxifylline; 
22 received standard (control) treatment. One patient from the control 
group died on day 20 from a heart attack. Two patients in the study 
group did not return for the blood viscosity measurement, and seven 
(three in the control group and four subjects in the study group) were 
lost to follow-up. Intention to treat analysis was performed so that 
all randomized patients were included in the analysis. The patient 
selection, treatment, and disposition are shown in Fig. 1.
Most patients (68%) were 50–80 years of age. The median was 55 
(range 19–70) years of age, 70% were men, 80% were hypertensive, 
64% were current smokers, 50% had dyslipidemia, 30% had diabetes 
mellitus, and 23% had ischemic heart disease. Lacunar stroke was the 
most common stroke type (86%), and the main manifestation was 
motor paralysis. There were no statistically significant differences 
in baseline demographic, clinical, or laboratory characteristics in the 
study and control groups (Tables 1 and 2).
Blood viscosity
The baseline blood viscosities in the study (6.46, range 5.20–9.73 
poise) and control (6.89 poise, range 5.57–14,10 poise) groups were 
not significantly different (p=0.105, Table 2). On day 7, the blood 
viscosity had decreased in both of the groups; however, the decrement 
was larger in the pentoxifylline group than in the control group (1.22 Fig. 1: Patients participating in this study
Table 1: Patient baseline demographic and clinical characteristics
Variable Study group (n=22) Control group (n=22) Total (n=44) p
Demographic variable
Age, y 55 (36–64) 55 (19–70) 14 (32%) 0.503**
18–49 6 (27%) 8 (36%) 30 (68% 0.517†
50–80 16 (73%) 14 (63%)
Sex
Male 14 (63%) 17 (77%) 31 (70%) 0.322†
Female 8 (36%) 5 (23%) 13 (30%)
Smoking
Yes 16 (73%) 12 (54%) 28 (64%) 0.210†
No 6 (27% 10 (45%) 16 (36%)
Clinical variable
Hypertension
Yes 18 (82%) 17 (77%) 35 (80%) 1.000†
No 4 (18%) 5 (23%) 9 (20%)
Diabetes mellitus
Yes 9 (41%) 4 (18%) 13 (30%) 0.099†
No 13 (59%) 18 (82%) 31 (70%)
Ischemic heart disease
Yes 5 (23%) 5 (23%) 10 (23%) 1.000†
No 17 (77%) 17 (77%) 34 (77%)
Dyslipidemia
Yes 10 (45%) 12 (54%) 22 (50%) 0.546†
No 12 (54%) 10 (45%) 22 (50%)
Stroke symptom
PACI 3 (14%) 3 (14%) 6 (14%) 1.000†
LACI 19 (86%) 19 (86%) 38 (86%)
Onset
<24 h 20 (91%) 17 (77%) 37 (86%) 0.412†
24–72 h 2 (9%) 5 (23%) 7 (16%)
NIHSS score 4.0 (1–11) 5.95±3.484 0.354**
†Chi-square test; †Fischer’s exact test; *unpaired t test, **Mann–Whitney U-test, p<0.05. NIHSS: National Institutes of Health Stroke Scale
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poise vs. 0.56 poise, p=0.465, Fig. 2). On day 30, the blood viscosity 
had decreased further; however, the decrement was not statistically 
significant (p=0.665, Fig. 2).
Clinical outcomes
Improvement in NIHSS score was achieved in 32% of the study group 
patients (relative risk [RR]=1.00; 95% confidence interval [CI]: 0.421–
3.556; p=1.00, Table 3). At the 1-month follow-up, the mRS and BI 
scores confirmed good functional and disability outcomes in 67% of the 
patients (RR=1.026; 95% CI: 0.656–1.605; p=0.909, Table 3).
DISCUSSION
The hematocrit, erythrocyte deformability, erythrocyte aggregation, 
and fibrinogen levels determine blood viscosity, the thickness, and 
stickiness of blood [7]. Blood hyperviscosity is present in most 
patients with acute ischemic stroke [14] and patients with stroke risk 
factors such as smoking, diabetes mellitus, dyslipidemia, and heart 
disease [15]. There were no significant differences in the presence of 
stroke-risk factors in the study groups. Hypertension was present in 
80% of the patients, consistent with the Indonesian demographic data 
that indicate hypertension as a principal risk factor for stroke [1]. Other 
risk factors present in this study population included smoking (64%), 
dyslipidemia (50%), diabetes mellitus (30%), and heart disease (23%). 
The incidence of stroke increased with age.
Pentoxifylline is a nonselective phosphodiesterase inhibitor used to treat 
intermittent claudication in patients with the peripheral arterial disease. 
Pentoxifylline significantly improves erythrocyte function, inhibits 
platelet aggregation, and decreases plasma fibrinogen, and blood viscosity 
in patients with cerebrovascular insufficiency [11]. The effectiveness of 
pentoxifylline was shown in this study by its effect on blood viscosity and 
association with the improvement of the clinical outcomes.
Mediators of inflammation such as tumor necrosis factor-α, interferon-β, 
interleukin (IL)-1β, and (IL-6) are released in the acute phase of stroke. 
Plasma fibrinogen also increases in the acute phase [16]. Blood viscosity 
increases in the acute stroke phase in response to inflammation and is 
also affected by coexisting stroke-risk factors [15]. Blood hyperviscosity 
contributes to stroke severity and outcome [14, 17-19].
Baseline blood viscosity was higher in control than in the pentoxifylline 
group; however, the difference (7.78 poise vs. 6.77 poise) was not 
significant. The blood viscosity had decreased from the baseline on 
both days 7 and 30. Blood hyperviscosity indicates a poor prognosis in 
patients with acute ischemic stroke. It leads to further loss of blood flow 
in the ischemic penumbra and can lead to the expansion of the infarct 
area and the worsening of the neurological deficit [5]. On day 7, the 
neurological deficit had improved in 32% of the patients in both groups 
(RR=1.00; 95% CI: 0.421–3.556; p=1.00, Table 3). On day 30, 67% of 
the pentoxifylline group and 68% of the control group had good clinical 
outcomes (RR=1.026; 95% CI: 0.656–1.605; p=0.909; Table 3). The 
similar clinical outcomes in both groups indicate that the standard acute 
stroke treatment that was given to all patients was adequate to improve 
the clinical outcome.
The study results differ from those reported by a double-blind, 
randomized trial of pentoxifylline in no hemorrhagic stroke patients. 
Intravenous pentoxifylline 1200 mg/day was given for 3 days and 
continued orally 400 mg t.i.d for the next 28 days. The neurological 
deficit improved but did not differ from the placebo control after the 
first few days. The improvements in the level of consciousness, motor 
function, and cranial nerve function were better in the study group than 
in the control group [20].
The study limitations include the small number of patients to assess the 
effect of pentoxifylline therapy for acute ischemic stroke and the loss of 
seven patients at the 1-month clinical evaluation.
CONCLUSION
A decrease in blood viscosity and improvement of clinical outcome 
was seen after pentoxifylline administration but was not significantly 
different from those seen in control patients with standard therapy 
after 7 days. The efficacy of pentoxifylline as an ischemic stroke therapy 
Fig. 2: The level of blood viscosity






Blood viscosity 6.46 (5.20–9.73) 6.89 (5.57–14.10) 0.105**
Hematocrit 45.41±5.89 43.52±3.64 0.108*
Leukocyte 9.197.62±2097.91 9.748.64±2.425.35 0.430*
Fibrinogen 362.72±118.72 384.62±±116.39 0.564*
LDL cholesterol 118.75±43.76 117±39.12 0.886*
HDL cholesterol 37±9.70 41.53±10.50 0.081*
Triglyceride 107.50 (57–234) 100 (65–280) 0.695**
*Unpaired t test, **Mann–Whitney U-test, p<0.05
Table 3: Clinical outcomes
Variable Study group Control group Total RR (95% CI) p
NIHSS improvement
Yes 7 (32%) 7 (32%) 14 (32%) 1.00 (0.421–3.556) 1.000†
No 15 (68%) 15 (68%) 30 (68%)
mRS (day 30)
Good 12 (67%) 13 (68%) 25 (67%) 1.026 (0.656–1.605) 0.909†
Poor 6 (33%) 6 (32%) 2 (33%)
BI (day 30)
Good 12 (67%) 13 (68%) 25 (67%) 1.026 (0.656–1.605)
Poor 6 (33%) 6 (32%) 12 (33%) 0.909†
†Chi-square test, p<0.05. NIHSS: National Institutes of Health Stroke Scale, mRS: Modified Rankin Scale, BI: Barthel index, CI: Confidence interval
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warrants investigation in a large clinical trial with more specific 
inclusion criteria to confirm these results.
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